Sanofi Files Suit in the U.S. to Defend its Patent Rights on Lantus®
August 08 2017 - 2:33PM
Sanofi Files Suit in the U.S. to Defend its
Patent Rights on Lantus®
Paris, France - August 8, 2017 - Sanofi announced today
that it filed a patent infringement suit against Merck Sharp &
Dohme Corp. ("Merck") on August 8, 2017 in the United States
District Court for the District of New Jersey. In its suit Sanofi
alleges infringement of two patents.
The suit was triggered by a notification received from Merck in
late June, in which Merck stated that it had filed an NDA
(505(b)(2) New Drug Application) with FDA for an insulin glargine
vial drug product. Merck also stated that its NDA included a
paragraph IV certification challenging all of the Sanofi patents
then listed in the FDA Orange Book for Sanofi's Lantus® and Lantus®
SoloStar® products.
About SanofiSanofi, a global healthcare
leader, discovers, develops and distributes therapeutic solutions
focused on patients' needs. Sanofi is organized into five global
business units: Diabetes and Cardiovascular, General Medicines and
Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer
Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New
York (NYSE: SNY).
Contacts:
Media
RelationsAshleigh KossTel: +1 (908) 981-8745Mobile: +1 (908)
205-2572Ashleigh.Koss@sanofi.com |
Investor RelationsGeorge Grofik Tel. +33 (0) 1 53 77 45
45ir@sanofi.com |
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/77fe10b9-ef21-49d6-82d8-04a6516ee80a
Sanofi (EU:SAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (EU:SAN)
Historical Stock Chart
From Apr 2023 to Apr 2024